<DOC>
	<DOCNO>NCT02132143</DOCNO>
	<brief_summary>The purpose study compare chemoradiation sequential chemoradiation Lung adenocarcinoma patient postoperative pN2 determines therapeutic method well patient .</brief_summary>
	<brief_title>Comparative Study Chemoradiation Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative pN2</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Clinical diagnosis Lung adenocarcinoma Postoperative stag pN2 period Voluntary participation inform consent Age ≥ 18 year old , male female , within six month weight loss le 10 % , tolerate radiotherapy performance status ( PS ) score 02 . Hemoglobin ≥ 80 g / L , white blood cell ≥ 4 × 109 / L , platelets ≥ 100 × 109 / L. Liver function : alanine aminotransferase ( ALAT ) , aspartate transaminase ( ASAT ) &lt; upper limit normal ( ULN ) 1.5 time , bilirubin &lt; 1.5 × ULN . Renal function : serum creatinine &lt; 1.5 × ULN . Compliance , regular followup , voluntary compliance study requirement Do meet inclusion criterion There evidence distant metastasis Suffered malignancy five year Within past January subject receive drug trial Having serious allergy idiosyncratic person , use folic acid , dexamethasone , vitamin B12 patient Severe lung heart disease , history Refuses unable sign inform consent participate trial The abuse drug alcohol addict . Patients difficult control bacterial , viral , fungal infection Having personality mental disorder , without civil capacity restrict civil capacity . Being pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Lung adenocarcinoma</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Sequential chemoradiotherapy</keyword>
	<keyword>Progression-free survival</keyword>
</DOC>